Spondyloarthritis & psoriatic arthritis
Performance of cut-offs of the ASAS Health Index to discriminate between treatment groups in patients with axial spondyloarthritis in the TICOSPA trial
Authors' conclusion
The data-driven thresholds of the ASAS HI identified in a longitudinal observational setting perform well in the context of a randomized trial.
Study context
- Population
- Patients with active axSpA treated in the TICOSPA randomised study; data from baseline and week 48all had ASAS HI data
- Participants
- 160 patients
- Comparison
- Performance of ASAS HI improvement and health-state thresholds in discriminating between trial arms and between responders and non-responders
- Primary endpoint
- Trial and longitudinal known group discrimination of ASAS HI thresholds of meaning for improvement and health states
- Follow-up
- Week 48
Methodological detailstight-controlled, treat-to-target trial, non-responder imputation (NRI) for missing data
- Tight-controlled, treat-to-target trial
- NRI for missing data
Primary result
As reported in the abstract
Trial discrimination of ASAS HI thresholds
OR range, absolute improvement outcomes
1.27 and 1.75
OR range, relative improvement outcomes
1.0 and 1.64
Further findings
Longitudinal discrimination: ASAS HI improvement ≥30 % or ≥ 3.0 points vs no significant improvement in global functioning
- Larger reduction in patient global and disease activity and more often remission
Health state: ASAS HI ≤ 5.0 achieved vs not achieved · week 48
- More likely to have ASAS partial remission, ASDAS inactive disease or ASDAS low activity
Original publication
Performance of cut-offs of the ASAS Health Index to discriminate between treatment groups in patients with axial spondyloarthritis in the TICOSPA trial. Semin Arthritis Rheum. Published 30 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →